Patents by Inventor Jianbin Ma

Jianbin Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compound Having Antitumor Activity And Use Thereof
    Publication number: 20240336593
    Abstract: The present disclosure provides a compound having a novel structure as a PRMT5 inhibitor, a method for preparing the compound, and use thereof in the treatment of a disease mediated by a PRMT5 inhibitor. Experiments have shown that these compounds have a strong inhibitory effect on PRMT5, and can be used as promising candidate compounds for treatment of diseases mediated by PRMT5 inhibitors. In addition, a specific synthetic method is developed in the present disclosure, which has a simple process and convenient operation, and is beneficial to industrial mass production and application.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 10, 2024
    Inventors: Qun Dang, Hanyu Yang, Pan Li, Chunhua Jiang, Zhou Yin, Jianbin Ma, Xiaodan Fu, Xin Cai
  • CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240150346
    Abstract: A compound, as represented by formula I, as a TLR7 agonist, a method for preparing the compound, and the use of the compound in treating diseases mediated by the TLR7 agonist are provided. Studies on the activity of a human-derived receptor, a TLR7 agonist, show that compounds have a strong agonistic effect on the human-derived receptor, TLR7, and can be used as a foreground compound for treating diseases mediated by the TLR7 agonist.
    Type: Application
    Filed: January 27, 2022
    Publication date: May 9, 2024
    Inventors: Yunlong SONG, Chen ZHANG, Fang GAO, Weimin LIU, Qun DANG, Pan LI, Zhou YIN, Xin CAI, Xiaodan FU, Jianbin MA
  • Heterocyclic compounds as arginase inhibitors
    Patent number: 11655260
    Abstract: Heterocyclic compounds are provided as arginase inhibitors, in particular to a compound represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof and a pharmaceutical composition including the compound.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 23, 2023
    Assignee: GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD.
    Inventors: Zhaoyin Wang, Nanxin Li, Jianbin Ma, Yanqiang Shao
  • ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS
    Publication number: 20220251116
    Abstract: Alkylboronic acids are provided as arginase inhibitors represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof and a pharmaceutical composition including compounds.
    Type: Application
    Filed: February 5, 2020
    Publication date: August 11, 2022
    Applicant: Guangdong Newopp Biopharmaceuticals Co., Ltd.
    Inventors: Zhaoyin Wang, Jianbin Ma, Yanqiang Shao, Nanxin Li
  • HETEROCYCLIC COMPOUNDS AS ARGINASE INHIBITORS
    Publication number: 20200325161
    Abstract: Heterocyclic compounds are provided as arginase inhibitors, in particular to a compound represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof and a pharmaceutical composition including the compound.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 15, 2020
    Applicant: Guangdong Newopp Biopharmaceuticals Co., Ltd.
    Inventors: Zhaoyin Wang, Nanxin Li, Jianbin Ma, Yanqiang Shao